1,2-dipalmitoylphosphatidylcholine and fasudil

1,2-dipalmitoylphosphatidylcholine has been researched along with fasudil in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Ahsan, F; Gupta, N; Gupta, V; Komatsu, M; McMurtry, IF; Mehvar, R; Nozik-Grayck, E; Oka, M; Shaik, IH	1
Asai, T; Fukuta, T; Honda, M; Namba, M; Oku, N; Yamamoto, H; Yanagida, M; Yanagida, Y	1

Other Studies

2 other study(ies) available for 1,2-dipalmitoylphosphatidylcholine and fasudil

Article	Year
Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension. Journal of controlled release : official journal of the Controlled Release Society, 2013, Apr-28, Volume: 167, Issue:2 Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1,2-Dipalmitoylphosphatidylcholine; Aerosols; Alkaline Phosphatase; Animals; Bronchoalveolar Lavage Fluid; Cell Line; Cell Survival; Cholesterol; Drug Stability; Familial Primary Pulmonary Hypertension; Hypertension, Pulmonary; L-Lactate Dehydrogenase; Liposomes; Macrophages, Alveolar; Male; Myocytes, Smooth Muscle; Protein Kinase Inhibitors; Pulmonary Artery; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; Vasodilation; Vasodilator Agents	2013
Release rate is a key variable affecting the therapeutic effectiveness of liposomal fasudil for the treatment of cerebral ischemia/reperfusion injury. Biochemical and biophysical research communications, 2020, 10-22, Volume: 531, Issue:4 Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1,2-Dipalmitoylphosphatidylcholine; Ammonium Sulfate; Animals; Brain; Citric Acid; Drug Carriers; Drug Compounding; Drug Delivery Systems; Drug Liberation; Liposomes; Male; Phosphatidylcholines; Quaternary Ammonium Compounds; Rats, Wistar; Reperfusion Injury; Treatment Outcome	2020

Article

Year

Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension.

Journal of controlled release : official journal of the Controlled Release Society, 2013, Apr-28, Volume: 167, Issue:2

Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1,2-Dipalmitoylphosphatidylcholine; Aerosols; Alkaline Phosphatase; Animals; Bronchoalveolar Lavage Fluid; Cell Line; Cell Survival; Cholesterol; Drug Stability; Familial Primary Pulmonary Hypertension; Hypertension, Pulmonary; L-Lactate Dehydrogenase; Liposomes; Macrophages, Alveolar; Male; Myocytes, Smooth Muscle; Protein Kinase Inhibitors; Pulmonary Artery; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; Vasodilation; Vasodilator Agents

2013

Release rate is a key variable affecting the therapeutic effectiveness of liposomal fasudil for the treatment of cerebral ischemia/reperfusion injury.

Biochemical and biophysical research communications, 2020, 10-22, Volume: 531, Issue:4

Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1,2-Dipalmitoylphosphatidylcholine; Ammonium Sulfate; Animals; Brain; Citric Acid; Drug Carriers; Drug Compounding; Drug Delivery Systems; Drug Liberation; Liposomes; Male; Phosphatidylcholines; Quaternary Ammonium Compounds; Rats, Wistar; Reperfusion Injury; Treatment Outcome

2020